Transgene is designing and developing next-generation immunotherapeutics against cancer

TG4001

 Positive Interim Analysis Results
of Phase II Trial

Evaluating TG4001 + Avelumab
vs Avelumab in HPV-Positive Anogenital Cancers

–> article annonceR&D

–> article annonceHome

Innovative technologies

Push the boundaries of immunotherapy

Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.

Discover our two therapeutic approaches
Discover our technologies

One patient, one cancer, one vaccine

With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.

myvac® video Discover myvac®

A new generation of products

These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.

Discover invir.IO

TG4001

A therapeutic vaccine in Phase II

TG4001 targets HPV-induced anogenital cancers.

More information

–> article Home actus

Two therapeutic approaches

Transgene’s immunotherapies harness the mechanisms of the immune response to enable the patient’s body to fight against disease. 

Press releases

See all press releases



Last publications

See all publications



Latest webcasts

A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer.